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Hypoxia determines survival outcomes of bacterial infection through HIF-1alpha 
dependent re-programming of leukocyte metabolism 
One Sentence Summary: Hypoxia reprograms the innate response to bacterial 
infection with consequence for host survival. 
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Abstract:  
Hypoxia and bacterial infection frequently co-exist, in both acute and 
chronic clinical settings, and typically result in adverse clinical outcomes. 
To ameliorate this morbidity, we investigated the interaction between 
hypoxia and the host response. In the context of acute hypoxia, both S. 
aureus and S. pneumoniae infections rapidly induced progressive 
neutrophil mediated morbidity and mortality, with associated hypothermia 
and cardiovascular compromise. Preconditioning animals through longer 
exposures to hypoxia, prior to infection, prevented these 
pathophysiological responses and profoundly dampened the transcriptome 
of circulating leukocytes. Specifically, perturbation of HIF pathway and 
glycolysis genes by hypoxic preconditioning was associated with reduced 
leukocyte glucose utilisation, resulting in systemic rescue from a global 
negative energy state and myocardial protection.  Thus we demonstrate 
that hypoxia preconditions the innate immune response and determines 
survival outcomes following bacterial infection through suppression of 
HIF-1a and neutrophil metabolism.  The therapeutic implications of this 
work are that in the context of systemic or tissue hypoxia therapies that 
target the host response could improve infection associated morbidity and 
mortality. 
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Introduction 
A close and bi-directional relationship between hypoxia and inflammation is well 
recognised. Hypoxia can induce inflammation, for example in acute mountain 
sickness, and inflamed tissues are typically hypoxic, in part due to oxygen 
consumption by inflammatory cells (1). Localised hypoxia is also a feature of 
tissues infected with a range of different pathogens (2, 3). Systemic hypoxia 
(hypoxemia) is a clinical characteristic of acute conditions, such as adult 
respiratory distress syndrome (ARDS) (4), and of chronic diseases such as 
COPD (5) but how hypoxemia modifies host responses to infection is largely 
unknown. 
  
Results 
Acute hypoxia induces rapidly progressive morbidity following local 
infection with Staphylococcus aureus. 
Staphylococcus aureus, an important human pathogen, is commonly found in 
critical care settings (6) where patients can be profoundly hypoxemic. Host 
responses to S. aureus infection depend critically upon the presence and 
functionality of myeloid cells, both in animals (7, 8) and humans (9).  We used a 
model of subcutaneous S. aureus infection to investigate the effects of systemic 
hypoxia on outcomes of infection. Subcutaneous S. aureus (SH1000 strain) 
produced a macroscopic skin lesion in normoxic mice, which developed over 7 
days and was well-tolerated (fig. S1, A to C). The same bacterial challenge in the 
setting of acute hypoxia (10% FiO2), however, caused significant and progressive 
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sickness behaviour and hypothermia (Fig.1, A, B, fig. S1, D, E). These responses 
were accompanied by bradycardia (Fig.1, C), hypotension (Fig.1, D), and 
impaired cardiac function, with reduced cardiac ejection fraction (Fig.1, E) and 
cardiac index (Fig.1, F, fig. S1, F) ultimately leading to death. Hypoxia-induced 
hypothermic responses to subcutaneous S. aureus were also observed with heat 
killed SH1000 (fig. S2, A), and replicated by intra-peritoneal administration of 
bacterial lipopolysaccharide (LPS) (fig. S2, B). Additional validation of the 
sickness phenotype was provided by radiotelemetry (fig. S2, C-F). The 
phenotype was confirmed in an outbred mouse strain (fig. S2, G) and 
independent of whether infection was during daytime or night-time (fig. S2, H, I). 
A graded phenotypic response was observed over a range of oxygen tensions 
21-10% O2 (Fig.1, G, H).  Importantly, this pathophysiological response occurred 
in the context of equivalent myeloid cell recruitment (fig. S3, A-C) and bacterial 
burden (fig. S3, D) with no evidence of S. aureus extravasation into the blood or 
seeding to kidneys, liver or spleen. 
In keeping with the observed morbidity, higher serum corticosterone and 
creatinine (fig. S4, A, B) levels were detected in hypoxia-exposed mice. A full 
SIRS response was not observed, however, with plasma cytokines either below 
the limits of detection (IL-1b, TNFa, IFNg, IL-10, IL-4, IL-13 and IL-22) or 
unchanged between hypoxic and normoxic mice (fig. S4, C-E), as were levels of 
the matrix metalloproteinase MMP9 (fig. S4, F), plasma nitrates (NO(X)) (fig. S4, 
G) and malondialdehyde (MDA), a marker of oxidative stress (fig. S4, H). The 
presence of nitrosylated tyrosine oxidative products in the skin was also 
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unaffected (fig. S4, I, J). Gross organ function was preserved under hypoxia with 
equivalent peripheral blood leukocyte profiles (marrow) (fig. S5 A), and normal 
serum aspartate transaminase (AST) (liver) and lipase (pancreas); circulating 
metabolic and stress responses (lactate, ATP, PGE2 and catecholamine levels) 
were also equivalent (fig. S5, B-H). There was no evidence of cerebrovascular 
leak, with undetectable levels of Evans blue dye in the brain tissue, and no 
evidence of lung injury, with equivalent wet-dry lung weight ratios, alveolar cell 
counts and lung architecture (fig. S6, A-D).   
 
Increased mortality is observed following systemic infection with 
Streptococcus pneumoniae in the setting of acute hypoxia. 
To define whether the morbidity observed with S. aureus in hypoxia was 
restricted to that organism or specific to the skin, where low oxygen tensions are 
reported in health (10, 11), we extended our experiments to a model of 
bacteremic pneumonia (12). In keeping with the S. aureus phenotype, challenge 
with intratracheal high-dose serotype 2 S. pneumoniae in the context of acute 
hypoxia resulted in increased sickness responses and associated hypothermia 
(Fig.1, I, J). This was again independent of bacterial burden, with equivalent lung 
CFU counts at 14 and 24h (Fig.1, K) and blood CFU counts lower at 14h and 
equivalent at 24h (Fig.1, L) when comparing hypoxic and normoxic animals. 
Reduced numbers of neutrophils and macrophages were recruited to the airways 
at 14h in hypoxia-exposed mice but cell counts were equivalent to normoxic mice 
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by 24h (Fig.1, M-O) and no differences in IgM levels, a marker of lung injury, 
were observed (Fig.1, P). Importantly, when infection was allowed to progress 
beyond 24h, approximately half of normoxic mice cleared the infection, while all 
hypoxia-exposed mice died (Fig.1, Q). Thus, at two different sites (skin and lung) 
and with two different pathogens (S. aureus and S. pneumoniae), combining 
infection with acute systemic hypoxia resulted in severe morbidity and later 
fatality, which occurred despite equivalent control of bacterial infection and 
absence of a typical SIRS response, oxidative damage or multi-organ failure.  
  
Hypoxic preconditioning prior to infection protects against the increase in 
morbidity and mortality observed with acute hypoxia. 
These profound acute physiological consequences of combined hypoxia and 
infection parallel human observations in the critical care setting, where increased 
mortality is described in hypoxemic patients who present with or develop 
bacterial infections (6, 13, 14). The clinical situation for chronic hypoxia is more 
complex. In COPD, for example, infective exacerbations and hypoxemia are 
each independently associated with disease progression (15, 16), yet bacteria 
are frequently present in the airways of clinically stable hypoxemic patients 
without severe systemic compromise (17). We therefore questioned whether 
more prolonged hypoxia could modify the systemic response to infection. Mice 
preconditioned for 7 days at 10% O2 prior to S. aureus infection showed marked 
protection from the acute hypoxia-associated systemic phenotype (Fig. 2, A, B). 
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Importantly, hypoxic preconditioning also reversed sickness and hypothermic 
responses and mortality observed with intra-tracheal administration of S. 
pneumoniae (Fig. 2, C-E). Hence preconditioning confers this protection following 
challenge by different bacterial pathogens, with different sites of infection, and in 
both localised and disseminated bacterial infections.  
 
Hypoxic preconditioning rescues the host from a global negative energy 
state. 
At a cellular level, adaptation to hypoxia critically depends upon co-ordinated 
metabolic responses that both maintain ATP production and modify energy 
requirements. The consequences of hypoxia and hypoxic preconditioning on 
metabolism were therefore explored. Indirect calorimetry revealed that animals 
infected in the setting of acute hypoxia preferentially switched towards 
carbohydrate utilisation in contrast to normoxia where fat and carbohydrates 
were proportionately consumed (Fig. 2, F).  In keeping with the suggestion of an 
increased reliance on glycolysis, hypoxic mice displayed a significant loss of liver 
glycogen (Fig. 2, G). Infection combined with acute hypoxia resulted in a 
negative energy state with loss of inguinal (white) and intrascapular (brown) 
adipose tissue (Fig. 2, H, I), increased serum ketone production (Fig.2, J) and 
lower circulating glucose levels in animals that succumbed to infection (Fig. 2, K).  
Hypoxic preconditioning rescued the animals from this negative energy state, 
with restoration of proportionate fat and carbohydrate consumption, liver 
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glycogen reserves and fat mass, reduction in circulating ketones and restoration 
of circulating fasting glucose and insulin levels (Fig. 2, F-M).  Furthermore, whilst 
brown fat glucose uptake was suppressed (Fig. 2, N), in vivo 18F-FDG PET 
studies identified enhanced glucose uptake by the myocardium following 
preconditioning (Fig. 2, O, P, fig. S7, A), with a parallel increase in cardiac 
function observed by measures of cardiac index and ejection fraction (Fig. 2, 
Q,R).  
 
Hypoxic preconditioning responses are retained in the circulating 
leukocyte population, with morbidity a neutrophil mediated response. 
To determine the longevity of the preconditioning response, mice experienced 1 
week of hypoxia before being maintained in normoxia for up to 28 days prior to 
bacterial challenge in hypoxia.  Protection was maintained even after 7 or 28 
days of normoxic re-acclimatisation (Fig. 3, A-D). Thus, the marked protection 
observed with hypoxic preconditioning extends significantly beyond the initial 
period of exposure.  
The importance of leukocyte populations in regulating outcomes following 
hypoxic preconditioning was explored in a series of bone marrow transfer 
experiments. Importantly, reconstitution of hypoxia-naïve mice with hypoxia 
preconditioned bone marrow, following fractional radiation (18, 19) to ensure 
selective targeting of the marrow population, conveyed protection from the 
morbidity (Fig. 3, E, F, fig. S7, B-D) and mortality observed in both infection 
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model systems (Fig. 3, G).  These results implicate circulating leukocyte 
populations both in driving the systemic phenotypes observed in acute hypoxia 
and in rescuing this response following hypoxic preconditioning. Anti-Ly6G 
(neutrophil) and clodronate (mononuclear cells) depletion (fig. S7, E) 
subsequently identified the hypoxia induced hypothermic responses to be 
neutrophil-dependent (Fig. 3, H). To address the mechanism by which 
preconditioning reprograms neutrophil glucose utilisation and protects against 
cardiac decompensation, we undertook RNA sequencing of circulating 
leukocytes following acute hypoxia in the presence or absence of infection with 
S. pneumoniae and of hypoxic preconditioning. Whilst global transcriptional 
states were largely unaltered between the four conditions (mean Pearson 
correlation score 0.88), a number of genes displayed strong expression changes, 
with the majority of changes a hallmark of preconditioning alone (Fig.3, I-K).   
 
Preconditioning represses leukocyte HIF pathway and glycolysis genes 
resulting in suppression of glucose utilisation and phenotypic rescue. 
Pathway analysis revealed unique signatures between the treatment groups (fig. 
S8), with suppression of HIF-1a pathway genes by preconditioning (fig. S9, A-C) 
further validated at both an RNA (Fig. 4, A, B) and protein level (Fig. 4, C). HIF-
1a is widely recognised to play a central role in co-ordinating cellular adaptive 
responses to hypoxia (20), including energy metabolism, and in regulating 
myeloid cell phenotypes (19, 21-24). Correlative heatmap analysis and 
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hierarchical clustering of the subset of 1,274 detected metabolic genes revealed 
distinct metabolic gene expression signatures between preconditioned and naïve 
states (Fig. 4, D).  Metabolic pathway analysis subsequently detailed the relative 
suppression of glucose transporters and key unidirectional glycolytic enzymes, 
validated by quantitative PCR (Fig. 4, E, fig. S9, D-F) and western blot (Fig. 4,C).  
A reduction in glycolysis following preconditioning was subsequently 
demonstrated by suppression of extracellular acidification rates (Fig. 4, F), with 
diminished glucose uptake by circulating and recruited leukocytes confirmed in 
vivo by 18F-FDG PET studies (Fig. 4, G, H).  Finally, to validate leukocyte HIF-1a 
expression as the critical mediator of systemic morbidity, HIF-1a 
(Hif1aflox/flox;LysMcre+/-) deficient mice were challenged with S. aureus.  Myeloid 
specific loss of HIF-1a (Hif1aflox/flox;LysMcre+/-), independent of effects either on 
local bacterial counts or systemic cytokine release (fig. S10, A-D), conveyed 
near-complete protection from the heightened sickness responses and 
hypothermia in hypoxia-exposed mice (Fig.4, I, J). This protection was equivalent 
to the effect of preconditioning alone (fig. S10, E).  Administration of a non-
selective pan hydroxylase inhibitor (DMOG) was unable to supress leukocyte HIF 
expression and therefore did not confer protection in this model system (fig. S10, 
F-H).  In keeping with metabolic protection, mice with myeloid-specific targeted 
deletions of HIF-1a (Hif1aflox/flox;LysMcre+/-) displayed higher circulating glucose 
levels following infection, even in the non-fasting state (Fig.4, K). 
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Discussion 
A significant body of work employing conditional knockout mice has developed 
our understanding of how the HIF hydroxylase pathway modifies myeloid cell 
function and survival.  Studies have delineated context specific roles for 
individual family members in the regulation of macrophage invasion and motility 
(21), macrophage bacterial killing (21, 22) and neutrophil survival (19, 23, 25) 
and phagocytosis (26), both in the setting of regional hypoxia and following 
bacterial infection.  The consequences of systemic hypoxia and bacterial 
infection acting in concert have not previously been examined in detail but are 
highly relevant to clinical situations, given the co-existence of systemic hypoxia 
and bacterial infection in e.g. the Adult Respiratory Distress Syndrome (ARDS) 
and of systemic hypoxia and bacterial colonisation of the airways in chronic 
obstructive pulmonary disease (COPD).  
Our studies in murine models of both localised and systemic acute infection in 
the setting of acute hypoxaemia, demonstrate the catastrophic in vivo 
consequences of exaggerated leukocyte HIF-1a activation.  Profound 
pathophysiological responses occur as a consequence of an imbalance in 
glucose availability and utilisation, with animals infected in the setting of acute 
hypoxia demonstrating a skewing toward carbohydrate utilisation, loss of liver 
glycogen stores, consumption of white and brown adipose tissue, elevated 
ketone production, and the eventual development of a circulating hypoglycaemia.  
Strikingly animals show preserved bacterial killing capacity despite metabolic 
compromise.  The equivalence of bacterial burden under each oxygen tension 
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studied together with the divergence between bacterial clearance and overall 
morbidity and mortality, thus indicate the importance of targeting the host 
response, in combination with an anti-microbial strategy to improve outcomes 
where hypoxia and infection co-exist.   
Hypoxia and infection can exist chronically e.g. in chronic obstructive pulmonary 
disease (COPD).  Experimental modelling of a more chronic state of hypoxia and 
bacterial infection showed we could ameliorate the observed increase in 
morbidity and mortality by prior exposure of animals to hypoxia.  This protection 
extended beyond the initial hypoxic exposure period, was sustained over time 
and both dependent upon and retained by the bone marrow compartment. These 
data suggest that hypoxic preconditioning changes bone marrow leukocyte 
populations which, when released into the circulation following bacterial 
challenge, demonstrate altered behaviours that in turn determine the host 
outcome.  Subsequent phenotypic rescue with anti-Ly6G depletion demonstrated 
the hypothermic and sickness responses were neutrophil mediated.  Thus, short 
lived circulating cells can possess functional memory of previous hypoxic 
challenges resulting in modified innate immune responses.  Whilst HIF-1a 
dependent training of responses to bacterial sepsis and a fungal cell wall 
component has been observed (27), our work provides the first evidence that 
oxygen availability is a critical determinant of morbidity and mortality outcomes 
following bacterial infection. 
Immune cell metabolism can profoundly influence key inflammatory responses. 
Macrophage polarisation states in part driven by metabolic processes.  Both anti-
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microbial M1 macrophages and neutrophils depend upon glycolysis, yet tissue 
repair M2 macrophages require fatty acid oxidation and oxidative 
phosphorylation for ATP production with the TCA cycle dominating over 
glycolysis (28-31).  Neutrophils in contrast demonstrate a disordered TCA cycle 
even in the resting state (32).   Consequences of metabolism for immune 
responses are therefore cell-type specific and will also vary in physiological and 
patho-physiological disease states.  In the models studied, we saw no effect of 
clodronate mediated mononuclear cell depletion on either hypoxia induced 
hypothermia or sickness whereas neutrophil depletion protected from the 
sickness response.  We therefore propose that neutrophil dependence upon 
glucose, whilst a beneficial adaptive response under normal systemic 
oxygenation, drives a fatal response in the context of systemic hypoxia where 
global glucose requirements are increased resulting in the development of 
hypoglycaemia and cardiac failure.  There are precedents that cell-type specific 
metabolic responses can influence the metabolism of other organs with 
consequences for the host.  As examples, skeletal muscle deletion of Phd2 
conveys protection from myocardial ischaemia reperfusion injury through the 
regulation of hepatic kynurenic acid production (33), whilst M2 macrophages can 
co-ordinate browning of subcutaneous white adipose tissue (34).  
We observed HIF-1a to be the critical mediator of the heightened sickness 
responses, with myeloid specific loss of HIF-1a conveying protection from 
hypothermia, sickness and hypoglycaemia following challenge with S. aureus.  
This is of interest, given that HIF-1a deficiency has previously linked to impaired 
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bacterial killing (21) and negative outcomes in more fulminant bacterial models 
(22).  Thus, the innate immune response must be exquisitely sensitive to HIF-1a 
levels of activity, with both insufficient (fulminant infection models) and excessive 
(acute infection and hypoxia) HIF-1a activation associated with poor outcomes, 
and hypoxic preconditioning enabling the restoration of this finely tuned 
response.  Understanding the mechanisms that regulate HIF-1a expression, 
stability and activity will therefore be critical in the development of strategies that 
target the innate immune response.  Whilst stabilisation of HIF-1a protein in 
innate immune cells is well characterised in the setting of hypoxia, regulation of 
HIF-activity has also been described following pathogen challenge (22), 
exposure to bacterial lipopolysaccharide cell membrane fraction (35) and iron 
chelation (36).  More recently small metabolite regulation of HIF-1a stability in 
both near-haploid cells (37) and CD8+ T-lymphocytes (38) has been described, 
with HIF-1 dependent accumulation of S-2-hydroxyglutarate (S-2HG) following T-
cell receptor triggering further augmenting HIF signalling in both normoxic and 
hypoxic culture conditions.  A further level of complexity is added with the 
observation that S-2HG can also inhibit the 2-oxoglutarate-dependent epigenetic 
modifiers that demethylate histones (Jumonji C containing proteins) or oxidise 5-
methylcytosine in DNA (Ten-eleven translocation (Tet) proteins)(39-41).  Thus in 
a model of T-cell receptor triggering changes in small metabolite abundance can 
both regulate HIF-1a expression and lead to alterations in epigenetic marks (38).  
These data combined with the evidence of innate immune training following 
repeated infectious challenge suggest that further exploration of the links 
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between individual metabolites, epigenetic changes, hypoxia and regulation of 
HIF pathway responses will be important in delineating the mechanisms by which 
hypoxia can re-program the neutrophil transcriptome, a limitation of our current 
study and an area of ongoing research activity. 
In summary we show outcomes of infection are profoundly regulated by 
neutrophil responses to oxygen and nutrient availability.  We identify a 
mechanism by which hypoxic preconditioning induces sustained changes in 
leukocyte glucose requirements and utilisation as a consequence of 
transcriptional suppression of leukocyte HIF-1a responses.  This in turn defines 
survival outcomes following local and systemic bacterial challenge, through a 
restoration of balance between glucose availability and tissue need and 
independent of recognised anti-microbial function.  Our work highlights the 
potential therapeutic importance of targeting the host response in combination 
with anti-microbial strategies when treating bacterial infection in the setting of 
hypoxia. 
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Materials and Methods 
Study design 
The goals of this study were to investigate the effects of ambient hypoxia on host 
responses to S. aureus and S. pneumoniae infection. We also determined the 
mechanisms by which hypoxic pre-conditioning prevented adverse outcomes in 
these infection models. Pilot experiments were performed to define the number 
of animals required to detect significant differences in body temperature and 
sickness score between infected animals exposed to hypoxia and those 
maintained in normoxia. Vehicle-treated animals were also exposed to hypoxia 
and assessed alongside infected animals. Other end-points included 
measurements of bacterial burden, serological and physiological parameters as 
stated under the sub-headings below. The number of biological replicates for 
each experimental group are indicated in the figure legends. In vivo experiments 
were performed independently at least twice unless otherwise specified. Clinical 
assessment of mouse sickness behavior was made by two independent 
observers blinded to which oxygen tension the mice had been exposed. Study 
design was approved with authorisation of our project licence in accordance with 
the Home Office Animals (Scientific Procedures) Act of 1986. 
 
Murine colonies 
Lysozyme M-driven cre recombinase (LysMcre) was used to target Hif1a 
(Hif1aflox/flox;LysMcre+/-) deletions in myeloid lineage cells. Animals were back 
crossed to a C57BL/6 background (21, 42). C57BL/6 mice or littermate LysMcre-/- 
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floxed mice were used as controls.  All animal experiments were conducted in 
accordance with the Home Office Animals (Scientific Procedures) Act of 1986 
with local ethics approval. 
 
Subcutaneous skin infection model 
SH1000, a strain of S. aureus derived from the clinical isolate NCTC 8325, was 
used throughout these experiments (43, 44). Mice were injected subcutaneously 
with live stationary phase bacteria (1 x 107 cfu) before being exposed to hypoxia 
(10% O2) or maintained in room air. At indicated time points (6 and 12 hours) 
mice were assessed alongside normoxic controls. Clinical assessments of 
mouse sickness behaviour were made and rectal temperature was recorded. 
Mice were anaesthetised, exsanguinated and tissues processed as described 
below or in supplementary methods.    
 
Blood pressure and heart rate measurements in awake mice 
To obtain readings in awake mice, animals were trained for 7 days to undergo 
non-invasive blood pressure measurement using a BP-2000 Blood Pressure 
Analysis System™ (Visitech Systems Inc., Apex, USA).  After training, these 
animals were then injected with either SH1000 bacteria or PBS and exposed to 
hypoxia or normoxia for 12 hours after which time blood pressure and heart rate 
measurements were recorded.  A minimum of 10 readings were attempted on 
each animal.   
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Echocardiography 
Twelve hours after subcutaneous injection of bacteria, hypoxic or normoxic mice 
were anaesthetised with 5% isoflurane supplied in oxygen at 2 l/min and placed 
on a warming pad.  Mice were secured on the pad lying flat and supine. The fur 
on the chest was clipped and hair removal cream used to ensure good 
penetration of ultrasound waves.  Transthoracic echocardiography was 
performed by an experienced operator using a VisualSonics Vevo® 770 Imaging 
system and RMV707B scanhead (VisualSonics, Toronto, Canada).   
 
Bone marrow transplantation 
C57BL/6 recipient mice were irradiated with 3 fractions of 1Gy each day for 4 
days before injection with 1.5x106 bone marrow cells from C57BL/6 mice 
exposed to hypoxia (10% O2) for 7 days or control C57BL/6 mice. S. aureus 
subcutaneous injection experiments were performed 4 weeks following injection 
of donor marrow, at a time point when tissue macrophages retain a native 
phenotype. 
 
RNA isolation and relative quantification 
Murine peripheral blood leukocytes (1x106/condition) were lysed and RNA 
extracted using the mirVana™ total RNA isolation protocols (Ambion, Austin, 
USA).  For RNA quantification, samples were treated with DNase (Ambion) and 
random hexamer cDNA synthesized by reverse transcription.  Assays-on-
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demand gene expression TaqMan® MGB 6FAM dye-labeled products (Applied 
Biosystems) were used for relative quantification of cDNA.   
 
Intratracheal pneumonia model 
Wild-type C57BL/6 mice were anaesthetized with ketamine (100mg/kg i.p.; 
Vetalar V, Pfizer, UK) and acepromazine (5mg/kg i.p.; Calmivet Solution 
Injectable, Vetoquinol, France). The fur was shaved from the neck and a small 
incision made. The trachea was then exposed by blunt dissection and cannulated 
with a 24G cannula (Jelco© radiopaque cannula, Smiths Medical International 
Ltd. Rossendale, UK). Each mouse then had 1x107 CFU of D39, type 2 
Streptococcus pneumoniae instilled via the trachea. Control animals were 
instilled by the same method with PBS. Mice were recovered for 6 hours and 
then exposed to hypoxia (10% O2) or maintained in room air. At indicated time 
points (14 and 24 hours) mice were assessed alongside normoxic controls. 
Clinical assessment of mouse sickness behaviour was made by two independent 
observers blinded as to which oxygen tension the mice had been exposed to, 
and rectal temperature was recorded. Mice were then culled and tissues 
harvested.  For preacclimatisaton experiments, mice were housed in 10% 
oxygen for 7 days prior bacterial challenge as described above.  For the Kaplan-
Meier plots, mice were culled once the threshold of sickness was reached. 
 
Assessment of lung injury 
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Bronchoalveolar lavage was performed via cannulation of the trachea. Total cell 
counts were calculated using haemocytometer counts and differential counts 
assessed on cytocentrifugation slides. Levels of IgM and elastase were analyzed 
using commercially available kits (Mouse IgM ELISA quantitation set, Bethyl 
Laboratories Inc, Montgomery, USA; EnzChek Elastase Assay Kit, Molecular 
Probes Europe BV, Leiden, The Netherlands). 
 
Quantification of viable bacterial counts 
10-fold serial dilutions were performed on whole blood aliquots. Three 10μl drops 
from each of 6 dilutions were then plated onto blood agar plates and cultured 
overnight in 37°C to calculate viable bacterial counts.  After collection of the 
bronchoalveolar lavage fluid, the lungs were carefully dissected and stored in 
sterile tubes. The lungs were homogenized and 10-fold serial dilutions performed 
on each sample to calculate viable bacterial counts, which were normalized to 
count per pair of lungs. 
 
Respiratory exchange ratios 
Mice were placed individually into a pre-calibrated home-cage indirect 
calorimetry Phenomaster system (TSE Systems, GmBH, Bad Homburg, 
Germany) for 1 hour and oxygen consumption, carbon dioxide production and X-
Y-Z activity by infra-red beam breaking were assessed.  Flow rate was set to 
0.3L/min.  Mice cages were sampled for 3 minutes and compared to an empty 
cage air reference every cycle in 15 minute blocks.  RER was calculated from O2 
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and CO2 measurements and the data presented as the average of cycles 2-4 of 
the one hour period. 
 
Liver histology 
Livers were placed in 10% buffered formalin prior to processing and staining with 
haematoxylin/eosin or Periodic Acid Schiff (PAS) reagents. 
 
Paired plasma biochemical profiling 
Animals were fasted for 6 hours prior to sacrifice, and blood collected at end 
point for glucose, insulin and  g-hydroxybutryate quantification by ELISA (Glucose 
HK:Sigma, Insulin:Crystal Chem, hydroxbutryate:Sigma, Missouri, USA). 
 
In vivo 18F-FDG-PET 
Circulating glucose levels were measured in animals at the time of radiotracer 
injection. Animals were injected with intra-peritoneal 18F-FDG (5.1±2.2 MBq, 
0.2±0.05 mL) 5 and 23 hours following the installation of intra-tracheal S. 
pneumonia.  After injection, mice were returned for 1 hour to their original 
ambient oxygen tensions prior to tissue harvesting for gamma counting or 
imaging in vivo under isoflurane anesthesia (1.5%, Oxygen 0.5 L/min, Nitrous 
Oxide 0.5 L/min) using a nanoPET/CT scanner (Mediso Medical Imaging 
Systems, Hungary).  A 30-min whole-body emission scan was obtained using a 
1:5 coincidence list mode. At the end of the emission scan, a CT scan was 
acquired (semi-circular full trajectory, maximum field of view, 480 projections, 55 
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kVp, 300 ms and 1:4 binning) for attenuation correction and co-registration with 
PET data. Three-dimensional PET data was reconstructed into 3×10 min frames 
using Mediso iterative Tera-Tomo 3D reconstruction algorithm and the following 
settings: 4 iterations and 6 subsets, full detector model, normal regularisation, 
spike filter on, voxel size 0.6 mm and 400-600 keV energy window. PET data 
was corrected for randoms, scatter and attenuation.  Reconstructed whole-body 
PET scans were imported into PMOD 3.4 software (PMOD Technologies, 
Switzerland) and volumes of interest (VOIs) were drawn around organs and 
tissues of interest. The measured activity of the target organs and tissues was 
expressed as the standard uptake values (SUV) corrected for circulating glucose 
levels (SUVglu).  Radioactivity levels of collected tissue samples were assessed 
using an automatic gamma counter (Wizard 1470 Gamma Counter, Perkin 
Elmer). Measured disintegrations per minute were converted to Becquerel and 
expressed in percentage injected dose per gram of tissue (%ID/g) and 
normalized to circulating glucose levels.   
 
Depletion of myeloid cell subsets 
Wild-type C57BL/6 mice were injected intraperitoneally with vehicle control, anti-
Ly6G antibody (500mg in 500ul per mouse, eBioscience, UK), clodronate or PBS 
containing liposomes (500ul per mouse, ClodronateLiposomes.com). Twelve 
hours later, the mice were challenged with subcutaneous SH1000 and housed in 
either normoxia (21% O2) or hypoxia (10% O2). At 12 hours following the 
challenge, clinical assessment of sickness was performed by two separate 
		
	
	
23	
observers and rectal temperature recorded. Mice were then anaesthetised and 
200uL of whole blood cell was collected into vials containing 2mM EDTA. Red 
cells were twice lysed in red cell lysis buffer (Biolegend) and cells were washed 
in FACS buffer (PBS+2mM EDTA+2%BSA). Cells were stained using Ly6C FITC 
(Biolegend), Lineage (CD3, CD19 (both Biolegend), Siglec F (BD Biosceinces) 
PE, CD115 APC (Biolegend), 7-AAD (Biolegend), CD45 AF700 (Biolegend), 
Ly6G Pacific Blue (Biolegend). Cells were acquired using a BD Fortessa 6 laser 
flow cytometer. 
 
RNA sequencing and analysis 
Murine peripheral blood leukocytes (1x106/condition) were lysed and RNA 
extracted using Qiagen mini total RNA isolation protocols (Qiagen, Germany). 
Samples were treated with DNase (Ambion), and sample integrity verified on the 
Agilent Bioanalyser with the RNA Nano chip.  Illumina Tru-seq paired end strand 
specific sequencing (Illumina, USA) was carried out on a NextSeq-550 
sequencer (Edinburgh Clinical Research Facility, Western General Hospital, 
Edinburgh, Scotland, UK). 500ng of Total RNA underwent ribosomal RNA 
depletion (rRNA) prior to purification, fragmentation, random hexamer cDNA 
generation and purification with AMPure XP beads (Beckman-Coulter, USA). 
Multiple indexing adapters were ligated to ds cDNA with subsequent 
hybridisation onto flow cells, and DNA fragment enrichment by 15 cycle PCR for 
sequencing.  Completed libraries were quantified by qPCR using the KAPA 
Illumina Library Quantification Kit (Illumina, USA) before multiplexing in two 
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equimolar pools and running on two flow cells on the Illumina NextSeq 550. The 
resulting FastQ files were mapped to the reference genome (mm9) using the 
Tophat alignment tool (V1) on Illumina Basespace software and reads per 
kilobase per million (RPKM) scores calculated.  Differentially expressed genes 
were identified using Cufflinks and the Differential expression tool on the Illumina 
Basespace software.  Genes showing greater than 2 fold change with Deseq 
generated P-values <0.05 were termed significant changers.  Global analysis of 
total RPKM datasets to determine overall trends on a gene to gene basis was 
carried out using R values and distances calculated by Euclidian and Ward 
methods with the resulting Pearson’s correlation scores plotted on a heat map.  
RPKM values for genes identified as being significantly different between the 
naïve infected (NI) and preconditioned infected (PI) datasets by Cufflinks were 
subsequently expressed as a Z-score heatmap with row normalized values.  
Signatures of expression change were calculated by stratifying the total dataset 
into groups displaying significant changes (P-value <0.05, 2 fold change) in 
RPKM score relative to the naïve control (NC) set as follows: up/down infection 
(altered expression in both naïve and preconditioned infection sets), up/down NI 
(altered expression only in the naïve infected set), up/down PI (altered 
expression only in the preconditioned infected set) and up/down preconditioning 
(altered expression in both the preconditioned naïve and infected states).   Go 
Term analysis was carried out on these gene lists using the David functional 
annotation tool (https://david.ncifcrf.gov).  Analysis of the Hif1α pathway was 
carried out using KEGG pathway annotations found at the KEGG pathway 
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database (http://www.genome.jp/kegg/pathway.html).  Metabolic gene 
expression analysis was performed in R on the subset of metabolic genes, 
defined as the union of genes in KEGG metabolic gene sets and genes of 
the iSS1393 mouse metabolic reconstruction PMID 23022739. Genes expressed 
at a level of at least 1 count per million reads in at least three of the samples 
were filtered out with the EdgeR package PMID 19910308 and differentially 
expressed genes and their false discovery rate (FDR) corrected p-values were 
identified by the limma package PMID 25605792. Heatmap analysis was 
performed using the D3heatmap package and significant clusters were 
calculated via multiscale bootstrap analysis with the Pvclust package PMID 
16595560. For pathway analysis gene expression data was mapped on KEGG 
metabolic pathways using the Pathview package PMID 23740750 and color-
coded according to the directionality of deregulation. 
 
Immunoblot detection of murine leukocyte protein 
Murine lysates were prepared by lysis in sodium dodecyl sulfate [SDS]). 
Immunoblotting was performed with polyclonal anti-mouse HIF-1a (Cell Signaling 
Technology) primary antibody. Sample loading was confirmed by p38 mitogen-
activated protein kinase (MAPK) expression (Cell Signaling Technology). All 
bands shown were at the predicted molecular weight for the protein of interest. 
 
Seahorse analysis of extracellular acidification 
Leukocytes were resuspended in XF assay media at a concentration of 3x106/ml. 
		
	
	
26	
Three million cells per condition were plated onto a XF24 cell plate pre-coated 
with CellTak (Corning, UK). The rate of extracellular acidification (ECAR) was 
measured at intervals of 7 minutes over a 90 minute cycle using a Seahorse 
XF24 (Seahorse Bioscience, USA). 
 
Statistical analysis 
Data were analysed using Prism 7.0 software (GraphPad Software Inc, San 
Diego, CA). For comparison of two sample means when cells from the same 
subject were used, paired t tests were performed. Unpiared t tests were used for 
comparisons between infected normoxic and hypoxic sample means, with one-
way ANOVA and Tukey’s post-tests used if the comparison also included a 
vehicle control group. If multiple time points or concentrations were used, 
repeated measures ANOVA with Dunett’s post tests were performed and if 
comparisons between normoxia and hypoxia or wild type and transgenic mice 
were required in these experiments, two-way ANOVA with Bonferonni post tests 
were performed. For bacterial counts, Kruskall-Wallis test with Dunn's multiple 
comparisons test was used. Survival was analyzed using a log-rank test. 
Statistical significance was accepted when p < 0.05. 
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Supplementary Materials:  
Materials and Methods 
Fig. S1 Hypoxia induces hypothermia, sickness behavior and cardiac dysfunction 
in mice infected subcutaneously with Staphylococcus aureus. 
Fig. S2 The phenotype observed in hypoxic infected C57BL/6 mice is reproduced 
by heat-killed SH1000, by intraperitoneal LPS, in an outbred mouse strain and 
following dawn or dusk infection. 
Fig. S3 Local immune responses are not impaired by hypoxia. 
Fig. S4 Mice display stress responses to hypoxia but no demonstrable systemic 
inflammatory or oxidative response. 
Fig. S5 Mice display preserved gross organ function in hypoxia. 
Fig. S6 No evidence of increased pulmonary oedema or pulmonary immune 
infiltration in hypoxic animals infected with Staphylococcus aureus. 
Fig. S7 Hypoxic preconditioning alters glucose uptake into tissues and protection 
is conveyed via the bone marrow. 
Fig. S8 Hypoxic preconditioning profoundly changes the global transcriptome of 
circulating leukocytes. 
Fig. S9 Hypoxic preconditioning alters the HIF-1a pathway and downstream 
targets in circulating leukocytes. 
Fig. S10 Preserved bacterial load, cytokine responses and preconditioning 
responses with myeloid specific suppression of HIF-1a. 
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Fig. 1. Hypoxia induces hypothermia, sickness behavior, cardiac dysfunction 
and mortality in mice exposed to regional or systemic bacterial infection. 
(A-H) Subcutaneous S. aureus infection.  Sickness scores (A), temperatures (B), 
heart rate (C) and systolic blood pressures (D) of mice were recorded 12 hours after 
injection of S. aureus or PBS vehicle (Veh) in normoxia (N, 21% O2) or hypoxia (H, 
10% O2) and after 12 hours in specified oxygen tensions (G, H).  Echocardiographic 
measurements of ejection fraction (E) and cardiac index (F) 12 hours after injection.  
(A) *** P = 0.000044, Normoxia vs. Hypoxia; n = 10; *** P = 0.00005, Hypoxia vs. 
Vehicle; n = 10 H, 5 Veh; (B) *** P = 0.000004, Normoxia vs. Hypoxia; n = 13; *** P 
= 0.00001, Hypoxia vs. Vehicle; n = 13 H, 5 Veh; one-way ANOVA with Tukey’s post-
tests. (C) * P = 0.0186, N vs. H; n = 5; * P = 0.0151, H vs. Veh H; n = 5 H, 3 Veh H; 
unpaired t tests. (E) *** P = 0.000753, N vs. H; n = 4; (F) * P = 0.0298, N vs. H; n = 
4; one-way ANOVA with Tukey’s post-tests. (G) *** P = 0.000003, 21% vs. 10%; *** 
P = 0.000036, 15% vs. 10%; ** P = 0.00217, 12% vs. 10%; (H) *** P = 0.000005, 
21% vs. 10%; *** P = 0.000004, 15% vs. 10%; ** P = 0.00109, 12% vs. 10%;  21% n 
= 9, 15% n = 5, 12% n = 5; 10% n= 9; one-way ANOVA with Tukey’s post-tests.(I-Q) 
Intra-tracheal S. pneumoniae.  Sickness scores (I) and temperatures (J) of mice 14h 
and 24h after intratracheal instillation of 107 cfu of S. pneumoniae D39 or vehicle (V) 
and housed in normoxia (N, 21% O2) or hypoxia (H, 10% O2). (I) * P = 0.0282, 14h 
N vs. H; n = 21 N, 15 H; (J) * P = 0.0459, 14h N vs. H; n = 21 N, 15 H; *** P = 
0.000036, 24h N vs. H; n = 8; one-way ANOVA with Tukey’s post-tests. (K, L) Viable 
bacterial counts recovered from homogenized lung (K) or whole blood (L) at 14h or 
24h after instillation of S. pneumoniae in specified oxygen tension. (L) * P = 0.0239, 
14h N vs. H; n = 21 N, 15 H; Kruskal-Wallis with Dunn’s post-test comparisons. Total 
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bronchoalveolar lavage (BAL) cell counts (M) and neutrophil (N) and macrophage 
(O) counts at 14h or 24h post instillation of S. pneumoniae or vehicle in specified 
oxygen tension. (M) ** P = 0.0034, 14h N vs. H; n = 21 N, 15 H; unpaired t-test. (N) 
** P = 0.01, 14h N vs. H; n = 21 N, 15 H; unpaired t-test; (O) * P = 0.0172, 14h N vs. 
H; n = 21 N, 15 H; unpaired t-test. (P) BAL supernatant IgM concentration in 
normoxia (N) and hypoxia (H) 14h and 24h after instillation. (Q) Kaplan Meier 
survival curves of mice instilled with S. pneumoniae and housed in normoxia or 
hypoxia. (Q) *** P = 0.0002 N vs. H; n = 10; log-rank test. Horizontal lines (A-B, G-
H, I-O) or bars (C-F, P) are mean +/- SEM.  
 
Fig. 2. Hypoxic preconditioning confers protection from hypothermia and 
sickness behavior and reverses the negative energy balance observed with 
infection in the setting of hypoxia. 
(A-B) Subcutaneous S. aureus.  Mice were preconditioned in hypoxia for 7 days 
then challenged with subcutaneous SH1000 and sickness scores (A) and 
temperatures (B) recorded after 12 hours. (A) * P = 0.0365 Hypoxia vs. 
Preconditioned; n = 7; (B) ** P = 0.00855 Hypoxia vs. Preconditioned; n = 7; 
unpaired t-tests. (C-P)  Intra-tracheal S. pneumoniae. Mice were instilled with PBS 
control (Veh) or S. pneumoniae (Spn) and housed in normoxia (N), hypoxia (H) or in 
hypoxia following preconditioning (Pre H).  Sickness scores (C) and temperatures 
(D) were recorded at 14 hours, and Kaplan Meier survival curves performed over a 
168-hour period (E). (C) ** P = 0.00114, Spn N vs. Spn H; ** P = 0.00114, Spn H vs. 
Spn Pre H; (D) * P = 0.00779, Spn N vs. Spn H; *** P = 0.0006, Spn H vs. Spn Pre 
H; n = 6 Spn N, 5 Spn H, 6 Spn Pre H; one-way ANOVA with Tukey’s post-tests; (E) 
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P = 0.0005, Normoxia vs. Hypoxia, P = 0.000012 Hypoxia vs. Pre H; n = 10; Log-
rank test. (F) Respiratory exchange ratios were calculated from indirect calorimetric 
analysis undertaken over a 1 hour period following a 20 hour exposure to S. 
pneumoniae. * P = 0.0230, N vs. H; * P = 0.0181, H vs. Pre H; n = 4; one-way 
ANOVA with Tukey’s post-test. Separately, 24 hours following infection, livers were 
harvested and PAS stained for glycogen (G), inguinal (H) and intrascapular (I) fat 
reserves measured by weight, serum b-hydroxybutyrate levels quantified (J) and 
blood glucose levels determined relative to survival outcome (K).  For accurate 
glucose monitoring, a sub group of mice were fasted for the last 6 hours of 
experimental procedure and paired glucose (L) and insulin (M) levels recorded.  (H) 
* P = 0.0429, Spn N vs. Spn H; * P = 0.0467, Spn H vs. Veh H; * P = 0.0208, Spn 
Pre H vs. Veh Pre H; n = 4; (I) ** P = 0.0041, Spn N vs. Spn H; ** P = 0.0078, Spn H 
vs. Spn Pre H; * P = 0.0219, Veh N vs. Veh H; n = 4; (J) * P = 0.0165 Spn N vs. Spn 
H, *** P = 0.000083, Spn H vs. Spn Pre H; n = 4; one-way ANOVA with Tukey’s 
post-tests. (K) **** P < 0.000001, survived (n = 25) vs. culled (n = 24); unpaired t-
test. (L) * P = 0.0101, N vs. H; * P = 0.0298, H vs. Pre H; n = 12 N, 9 H, 9 Pre H; 
unpaired t-tests; (M) * P = 0.0106, N vs. H; n = 12 N, 9 H; unpaired t-test. In a 
separate group of animals, 18F-FDG was administered 5 hours (N) and 23 hours 
following instillation of S. pneumoniae (SPn) (O, P). Radioactivity levels were 
assessed with a gamma counter on brown fat (N) and hearts (P) and in vivo 
standardized glucose uptake values determined by positron emission tomography 
(PET) (O). (N) * P = 0.0177, Spn N vs. Spn H; * P = 0.0185, Spn H vs. Spn Pre H; n 
= 4 Spn N, 4 Spn H, 3 Spn Pre H; one-way ANOVA with Tukey’s post-test. (P) * P = 
0.0307, Spn N vs. Spn Pre H; * P = 0.0237, Spn H vs. Spn Pre H; n = 3 Spn N, 4 
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Spn H, 4 Spn Pre H; one-way ANOVA with Tukey’s post-test. (Q, R)  Subcutaneous 
S. aureus.  Echocardiographic measurements of ejection fraction (Q) and cardiac 
index (R) were undertaken 12 hours after injection of S. aureus in normoxia (N), 
hypoxia (H) or in hypoxia following preconditioning (Pre H). (Q) *** P = 0.000485, N 
vs. H; n = 4 N, 6 H; * P = 0.0132, H vs. Pre H; n = 6; (R) ** P = 0.00133, N vs. H; n = 
4 N, 6 H; *** P = 0.00041, H vs. Pre H; n = 6; one-way ANOVA with Tukey post-
tests. Horizontal lines (A-D, N, P) or bars (F, H-M, Q, R) are mean +/- SEM.  
 
Fig. 3. Hypoxic preconditioning confers long-term protection from adverse 
responses to infection in hypoxia and changes the transcriptome of 
circulating leukocytes. 
(A-D) Duration of preconditioning effect.  Mice were preconditioned in hypoxia for 7 
days, SH1000 injected subcutaneously after either 7 days (A, B) or 28 days (C, D) 
back in normoxia and sickness scores (A, C) and temperatures (B, D) recorded after 
a further 12 hours. (B) * P = 0.0203; n = 5; (C) * P = 0.0142; n = 6 H, 7 Pre H; (D) * 
P = 0.0238; n = 6 H, 7 Pre H; unpaired t-tests. (E-G) Bone marrow transfer.  Mice 
were preconditioned in hypoxia for 7 days, bone marrow harvested and injected into 
wildtype C57BL/6 mice pre-irradiated with 12 fractions of 1Gy (Pre H to WT), with 
non-preconditioned mice used as marrow donor controls (Un to WT).  Following 3 
weeks re-constitution mice were challenged either with subcutaneous SH1000 in 
hypoxia (E, F) or intra-tracheal S. pneumoniae (G).  Sickness scores (E) and 
temperature (F) were recorded after 12 hours. (E) * P = 0.0444 Pre H to WT vs. Un 
to WT; n = 6 Pre H to WT, 5 Un to WT; unpaired t-test. (G) Kaplan Meier survival 
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curves were undertaken of mice instilled with S. pneumoniae and housed in 
normoxia or hypoxia. *** P = 0.0007, Normoxia vs. Hypoxia; * P = 0.0305, Naive BM 
hypoxia vs. Pre BM hypoxia; n = 8; log-rank test. (H) Myeloid cell depletion. 12 
hours following injection with vehicle control (PBS), anti-Ly6G antibody (Ly6G), 
clodronate (Clod) or control liposomes containing PBS (Lipo), animals were 
challenged with subcutaneous SH1000 and rectal temperatures measured after 12 
hours. **** P = 0.00000002, Normoxia PBS vs. Hypoxia PBS; * P = 0.0235 Hypoxia 
PBS vs. Hypoxia Ly6G; * P = 0.0146, Hypoxia Ly6G vs. Hypoxia Clod; n = 8 N PBS, 
7 H PBS, 7 N Ly6G, 7 H Ly6G, 8 N Clod, 8 H Clod, 3 N Lipo, 3 H Lipo; 2-way 
ANOVA with Tukey’s post-test. Horizontal lines (A-F, H) are mean +/- SEM. (I-K)  
RNA-seq.  Blood leukocytes were harvested from hypoxia naïve mice instilled with 
S. pneumoniae in 10% O2 (naïve infected, NI) or vehicle control (naïve control, NC) 
or following hypoxic preconditioning (preconditioned infected, PI and preconditioned 
control, PC). (I) Pearson correlation heatmap analysis with hierarchical clustering 
on total RNA-seq datasets. Pearson correlation scores are plotted from 0 (white) 
to 1(dark blue) in steps of 0.1. (J) Heatmap of column normalized Z-scores for 
each gene identified as changing significantly between the naïve infected and 
preconditioned infected samples. Blue: Z-score -2, Yellow: Z-score +2.  (K) 
Signatures of differential gene expression across the datasets. Genes were selected 
based on fold change values >2 fold induced or repressed relative to naïve control 
expression status (=1). Numbers of genes per group are shown in square brackets 
above the plots.  
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Fig. 4. Repression of leukocyte HIF-1a suppresses glucose utilization 
resulting in phenotypic rescue. 
(A-C) HIF-1 expression.  Leukocytes were harvested from mice injected with 
SH1000 (A) or S. pneumoniae (Spn) (B, C) in normoxia (N, 21% O2), hypoxia (H, 
10% O2) or in hypoxia following hypoxic pre-conditioning (Pre H). RNA and protein 
were extracted and relative expression of Hif1a and Hif1b RNA normalized to Actb 
(A, B) with protein to P38 (C). (B) Hif1a * P = 0.0447, H vs. Pre H; n = 6 N, 7 H, 6 
Pre H; unpaired t-test; Hif1b * P = 0.0272, H vs. Pre H; n = 6 N, 7 H, 6 Pre H; 
unpaired t-test. (D-E) Metabolic gene expression analysis. Correlation heatmap and 
hierarchical clustering analysis was undertaken of metabolic transcripts identified 
within the RNA-seq dataset of blood leukocytes harvested 14 hours after intra-
tracheal installation of S. pneumoniae (Spn) in normoxia (N), hypoxia (H) or in 
hypoxia following preconditioning (Pre H).  Color scale: red, higher correlation; blue, 
lower correlation, with significance determined by multi-scale bootstrap analysis 
(P<0.01) and represented by changes in color within the dendrogram (D). The log 
fold change of individual glycolytic enzyme transcripts was determined for 
preconditioned leukocytes relative to naïve controls (green: upregulated by at least 
by 60 %; orange: downregulated by 60%) (E). Changes in transcript abundance 
were further validated in the SH1000 model by real time PCR (E). (E) Glut1 * P = 
0.0168, N vs. H; ** P = 0.0082, H vs. Pre H; Tpi1 ** P = 0.0074, N vs. H;  Gapdh ** P 
= 0.0015, N vs. H; * P = 0.0345, H vs. Pre H; Pkm * P = 0.0460, H vs. Pre H; n = 6 
N, 6 H, 5 Pre H; one-way ANOVA with Tukey’s post-tests. (F-H) Functional changes 
in metabolism. (F) Leukocytes were harvested from mice challenged with 
subcutaneous PBS or SH1000 and housed in normoxia (N), hypoxia (H) or in 
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hypoxia following preconditioning (Pre H).  Glycolytic rates following infection were 
indirectly measured by extracellular acidification rates (ECAR) relative to vehicle 
controls. *** P = 0.0007, N vs. H; * P = 0.0466, N vs. Pre H; * P = 0.0114, H vs. Pre 
H; n = 3, one-way ANOVA with Tukey’s post test. (G-H) 18F-FDG was administered 5 
hours following instillation of S. pneumoniae (Spn) and radioactivity levels in 
harvested blood leukocytes (G) and bronchoalveolar lavage (BAL) cells (H) 
assessed after 1 hour by gamma counts. (G) * P = 0.0269, H vs. Pre H; n = 4 N, 3 
H, 4 Pre H; (H) * P = 0.0124, H vs. Pre H, n = 3 N, 4 H, 4 Pre H; one-way ANOVA 
with Tukey’s post-tests. (I-K) Myeloid loss of HIF-1a. Sickness scores (I) and rectal 
temperatures (J) were determined in wild-type C57BL/6 (WT) and 
Hif1aflox/flox;LysMCre+/- (Hif1a-/-) mice 12 hours following subcutaneous injection of 
SH1000. (I) ** P = 0.00144 WT H vs. Hif1a-/- H; n = 8 WT H, 10 Hif1a-/- H; (J) *** P = 
0.000545 WT H vs. Hif1a-/- H; n = 7 WT H, 10 Hif1a-/- H; 2-way ANOVA with Tukey’s 
post-tests. (K) In a separate group of animals random glucose levels were 
measured in wild-type (WT) and Hif1aflox/flox;LysMCre+/- (Hif1a-/-) mice 20 hours 
following infection with S. pneumonia in 10% O2. * P = 0.0158, WT vs. Hif1a
-/-; n = 
21 WT, 23 Hif1a-/-; unpaired t-test.  
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